From the Lab to the Clinic: Swiss Study Confirms Real-World Effectiveness of Psychedelic Therapy for Depression and Anxiety

Posted: April 28, 2026

Key Points

•A large-scale study in Switzerland provides strong real-world evidence for the effectiveness of psychedelic-assisted psychotherapy.

•Patients with treatment-resistant depression and anxiety showed significant symptom reduction after treatment.

•Both LSD and psilocybin were found to be comparably effective and safe in a routine clinical care setting.

•The treatment was well-tolerated, with most adverse events being mild and transient, and it led to healthier emotional regulation strategies.

•These findings are a critical step in moving psychedelic therapy from highly controlled research trials into mainstream clinical practice.

For years, the headlines have been filled with promising results from controlled clinical trials of psychedelic-assisted therapy. In the pristine, carefully selected environments of research labs, substances like psilocybin and LSD have shown remarkable potential for treating severe depression and anxiety. But a crucial question has always lingered: will these treatments work in the messy, complex reality of everyday clinical practice? A landmark 2026 study from a university hospital in Switzerland has provided a resounding answer: yes.

This article will dive into the findings of this large-scale study, which tracked over a hundred patients undergoing psychedelic-assisted psychotherapy as part of a compassionate use program. We will explore the significant reductions in depression and anxiety symptoms observed, compare the effectiveness of LSD and psilocybin, and examine the safety of this treatment in a real-world setting. This research marks a pivotal moment, offering a much-needed bridge from the controlled world of the lab to the practical reality of the clinic, and providing tangible hope for those who have not found relief with conventional treatments.

What Makes a “Real-World” Study Different?

A “real-world” study evaluates a treatment as it is used in routine clinical practice, rather than in the highly controlled and often idealized conditions of a randomized controlled trial (RCT). This includes a more diverse patient population with complex, co-occurring conditions, providing a more accurate picture of a treatment’s effectiveness and safety for the average person seeking help (1, 2).

While RCTs are the gold standard for proving a treatment can work under ideal circumstances, they often exclude patients with multiple diagnoses or complex histories. Real-world studies, on the other hand, embrace this complexity. They tell us how a therapy performs for actual patients in a typical clinical setting, with all the variability that entails. This type of evidence is essential for doctors, patients, and policymakers to understand how a new therapy will truly function when it becomes widely available.

What Did the Swiss Real-World Study Find?

The study, which analyzed data from 115 patients with treatment-resistant depression and/or anxiety, found that a single cycle of psychedelic-assisted psychotherapy led to significant and clinically meaningful reductions in both depressive and anxiety symptoms. These improvements were observed 1-3 months after the treatment session, indicating a sustained benefit from the therapy (1).

This is a critical finding. The patients in this cohort were not research subjects cherry-picked for a trial; they were individuals for whom standard treatments had failed, seeking help through a legal, compassionate use program. The fact that they experienced such significant improvements demonstrates that the promise of psychedelic therapy is not just a laboratory phenomenon. It holds true in the real world, offering a viable new option for some of the most difficult-to-treat mental health conditions, such as severe anxiety.

Were Psilocybin and LSD Both Effective?

Yes, the study found that both psilocybin (25 mg) and LSD (100 µg) were comparably effective in reducing symptoms of depression and anxiety. There was no significant difference in the clinical outcomes between the two substances, suggesting that both can be used effectively within a therapeutic framework. The treatment was also found to improve patients’ cognitive emotion regulation, helping them to reduce self-blame and rumination and increase positive coping strategies (1, 3).

This finding is important because it provides clinicians with more than one tool for psychedelic-assisted psychotherapy. While the subjective experience of LSD and psilocybin can differ in duration and character, this study shows that, when used in a supportive therapeutic context, both can lead to similar positive mental health outcomes. The improvements in emotion regulation are also key, as they suggest the therapy doesn’t just reduce symptoms, but helps patients build the psychological skills needed for long-term well-being.

Was the Treatment Safe in a Real-World Setting?

The treatment was found to be very safe and well-tolerated. The adverse events recorded on the day of treatment were mostly mild and transient, such as temporary anxiety or physical discomfort. Crucially, there were no serious complications, and no patients had to discontinue treatment due to adverse effects. This provides strong evidence that, when conducted in a specialized and professional medical setting, psychedelic-assisted psychotherapy is a safe procedure (1, 4).

Safety is a paramount concern for any new treatment, and this study provides robust reassurance. The compassionate use program in Switzerland operates under strict medical supervision, demonstrating that a framework of care, preparation, and support is key to ensuring patient safety. This is why the process of psychedelic integration with a trained professional is so vital. This real-world safety data is a crucial piece of the puzzle, helping to build trust and confidence in this emerging therapeutic model. You can read more about the growing acceptance of these treatments in our post, Why Psychedelic Therapy is Gaining Mainstream Acceptance.

Hope and Healing in the Real World

The findings from this Swiss study are more than just data points; they are a beacon of hope. They confirm that the transformative potential of psychedelic-assisted psychotherapy is not confined to the lab but can be realized in the complex reality of clinical care. For the millions of people who suffer from treatment-resistant depression and anxiety, this research opens the door to a new and powerful avenue for healing.

This is a major step forward in the journey to integrate these medicines into mainstream mental healthcare. It demonstrates that with the right framework of safety, support, and professionalism, we can unlock the profound healing potential of these remarkable compounds for conditions like PTSD and depression. The future of mental health treatment is evolving, and it is brighter and more hopeful because of this kind of rigorous, real-world research.

If you have struggled to find relief from depression or anxiety with traditional methods, you are not alone. We are here to help you explore all paths to healing. Contact us today to learn more about our compassionate and evidence-informed approach to mental wellness.

About the Author

This article was written by Jeff Jones, a Licensed Professional Counselor (LPC) in Texas in practice 27 years. He is a 2024 graduate of the CIIS Center for Psychedelic Therapies and Research program. With a compassionate and evidence-based approach, he helps clients navigate life’s challenges and find a path toward healing.

Disclaimer

The information in this article, including discussions of psychedelic-assisted psychotherapy, is for informational purposes only. Psychedelic-assisted psychotherapy has not been approved by all regulatory agencies in the United States, and its safety and efficacy are still being established. This content is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

(1) Aboulafia-Brakha, T., et al. (2026). Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland. Psychiatry Research, 358, 116992. https://www.sciencedirect.com/science/article/pii/S0165178126000533

(2) Gründer, G., et al. (2026). Compassionate use of psilocybin for treatment-resistant depression in Germany. The Lancet Psychiatry, 13(2), 91-93. https://pubmed.ncbi.nlm.nih.gov/40976246/

(3) Holze, F., et al. (2022). Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a randomized controlled trial. Neuropsychopharmacology, 47(6), 1180-1187. https://www.nature.com/articles/s41386-022-01297-2

(4) Liechti, M. E., et al. (2025). Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program. Neuroscience of Consciousness. https://www.sciencedirect.com/science/article/pii/S2772408525001176